Understanding the genetic sequence of individual patients is becoming a central feature of medical care. This is particularly true in human cancer where the accumulation of genetic alterations in the tumor represents a universal feature of the disease and can be important for determining optimal therapy and for monitoring disease. Personal Genome Diagnostics (PGDx) was launched in 2010 to bring state-of-the-art genetic analyses to cancer patients. The founders of PGDx are international leaders in cancer genetics and were the first to perform genome-wide sequence analyses of human cancer. PGDx has developed proprietary methods to perform patient-specific analyses of the cancer genome using digital characterization and monitoring technologies.
